Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating mosunetuzumab in combination with chemotherapy for untreated C-MYC rearrangement-positive high-grade B…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) [Phase 2]
A Phase 2 feasibility trial of glofitamab for diffuse large B-cell lymphoma using interim FDG PET and ctDNA to optimize initial therapy; the…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating the combination of epcoritamab, rituximab, gemcitabine, and oxaliplatin (R-GemOx) as salvage therapy befor…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma [Phase 2]
Phase 2 trial update on CD70 CAR NK cells for primary refractory or early-relapsed diffuse large B-cell lymphoma and Hodgkin lymphoma; the s…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 1]
A Phase 1 clinical trial is evaluating a triple-drug regimen consisting of mosunetuzumab, polatuzumab vedotin, and lenalidomide for relapsed…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) [Phase 3]
This is a Phase 3 study evaluating Zilovertamab Vedotin in combination with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP)…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers [Phase 1]
Phase 1 safety study update for PF-08046044/SGN-35C in adults with advanced cancers; the trial is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma [Phase 1]
Phase 1 clinical trial evaluating mosunetuzumab consolidation after autologous stem cell transplantation in relapsed/refractory aggressive B…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy [Phase 3]
A Phase 3 trial is evaluating KITE-753 versus Axicabtagene Ciloleucel for relapsed or refractory diffuse large B-cell lymphoma after first-l…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial update on TTI-622 in combination with pembrolizumab for relapsed or refractory diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma [Phase 1]
This ClinicalTrials.gov update describes an ongoing Phase 1 study of 19(T2)28z1xx TRAC-CAR T cells in patients with B-cell lymphomas, includ…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies [Phase 1, Phase 2]
This is a Phase 1/2 dose-escalation and expansion study of BGB-16673 in patients with various B-cell malignancies and is currently recruitin…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating the effectiveness of ViPOR in relapsed/refractory aggressive B-cell lymphomas; the study includes Diffuse …
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma [Phase 2]
Phase 2 clinical trial at Beijing Tongren Hospital evaluating a CD19/CD22 bispecific CAR-T cell therapy for relapsed/refractory diffuse larg…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation Concept [Phase 2]
Phase 2 clinical trial evaluating a glofitamab-based induction and consolidation strategy for high-risk second-line relapsed/refractory diff…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL [Phase 3]
Phase 3 trial evaluating AZD0486 as first-line therapy for elderly or unfit patients with diffuse large B-cell lymphoma is currently recruit…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL [Phase 3]
Clinical trial update for a Phase 3 study of Brentuximab Vedotin with Lenalidomide and Rituximab in relapsed/refractory Diffuse Large B-Cell…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers [Phase 1]
This document outlines an ongoing Phase 1 trial evaluating NKX019, an allogeneic CAR NK cell therapy, in adults with B-cell cancers includin…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial update evaluating zanubrutinib in combination with sonrotoclax for relapsed or refractory B-cell non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) [Phase 2, Phase 3]
A phase 2/3 clinical trial evaluating Zilovertamab Vedotin (MK-2140) with standard of care in relapsed or refractory diffuse large B-cell ly…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating acalabrutinib in combination with DA-EPOCH-R or R-CHOP for patients with untreated diffuse large B-ce…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma [Phase 1, Phase 2]
This document outlines a Phase 1/2 clinical trial (ViPOR) evaluating a combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and l…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) [Phase 2]
This Phase 2 trial compares zilovertamab vedotin plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) against Polatuzumab v…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial update for a novel combination therapy in relapsed or refractory aggressive B-cell lymphoma (diffuse large B-cell lym…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Study of Out of Specification for Tisagenlecleucel [Phase 3]
This document reports a Phase 3 clinical trial update for tisagenlecleucel (Kymriah) addressing an out-of-specification issue, for indicatio…